Bryce Point Capital LLC Acquires Shares of 6,763 Hologic, Inc. (NASDAQ:HOLX)

Bryce Point Capital LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,763 shares of the medical equipment provider's stock, valued at approximately $488,000.

Other institutional investors have also recently made changes to their positions in the company. General Partner Inc. purchased a new stake in Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment increased its stake in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC increased its stake in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Trading Down 3.8 %

HOLX stock traded down $2.24 during midday trading on Thursday, reaching $57.07. 1,102,299 shares of the company traded hands, compared to its average volume of 1,885,215. The firm has a market capitalization of $12.81 billion, a price-to-earnings ratio of 17.98, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 52-week low of $56.51 and a 52-week high of $84.67. The business has a 50 day moving average of $63.03 and a 200-day moving average of $71.87. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Remove Ads

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent analyst reports. Raymond James reissued an "outperform" rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Citigroup decreased their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Evercore ISI dropped their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.